Evonik stock heads into the open after a 1.0 percent Xetra loss

At the close on September 17, 2026, Evonik stock finished at 17.39 euros on Xetra, down 1.02 percent, slightly underperforming the MDAX. An analyst warning on risks in the animal nutrition segment weighed on the shares in the last session.

Evonik stock closed at 17.39 euros on Xetra on September 17, 2026, marking a decline of 1.02% from the previous session. The share slipped more than the broader MDAX on the day, as an analyst warning about risks in the animal nutrition business put pressure on the price.

September 17, 2026 in numbers

Evonik Industries AG (ISIN DE000EVNK013, Xetra: EVK) ended the September 17, 2026 Xetra session at 17.39 euros, compared with 17.46 euros on September 16, 2026, corresponding to a 1.02% daily loss. According to a wrap citing Xetra data on mid-September trading, the stock was described as one of the weaker MDAX names, with the move linked to cautious investor sentiment after an analyst highlighted limited upside and segment risks in animal nutrition, as reported by Ad-hoc-news. The article notes that the analyst commentary left only around 3% upside to the stated price target, which contributed to the market's focus on the risk profile of the animal nutrition segment and helped explain the stock's weaker performance versus the MDAX on September 17, 2026. Within that MDAX context, Evonik's 1.02% drop was moderate but noticeable, while some index constituents fell much more sharply.

Today's outlook for Evonik

Today, September 18, 2026, Evonik enters the new session with the previous Xetra close of 17.39 euros as the latest reference point and with investor attention still shaped by recent analyst commentary on animal nutrition risks. The company's investor relations and financial calendar around mid-September 2026 indicate regular ongoing engagements with the capital markets, and the MDAX framework means the stock will continue to react to broader moves in European equities and sector peers, especially in chemicals, materials, and specialty ingredients. In addition, developments in macroeconomic data, interest rate expectations, and industrial demand indicators over the coming days can influence sentiment toward Evonik, given its exposure to cyclical end markets and specialty applications, even though no specific dated company event stands out for today within the near-term window.